Two of the 5 arms will administer 2 optimal dosing regimens as monotherapy with SB 9200. Two of the 5 arms in Part B will administer the same 2 optimal doses from Part A and tenofovir 300 mg QD. The fifth arm will administer tenofovir 300 mg QD as monotherapy.